Consensus Genmab A/S

Equities

GMAB

DK0010272202

Real-time Estimate Cboe Europe 07:23:22 17/07/2024 pm IST 5-day change 1st Jan Change
1,835 DKK +0.40% Intraday chart for Genmab A/S +3.31% -15.38%

Evolution of the average Target Price on Genmab A/S

Price target over the last 5 years

History of analyst recommendation changes

9f6bb4ae562fb531674e2cd6e8be8e.fSU5GD2pEEPCftN6WbCh2Gv54NtltuAkVYZgg5dzz1Y.LGR6SEzMYyeUP4tCC4TRoC21j74s0M1QN80B5q4epg8sSkNJT_xhbposng~57ce80de300723d1e84a8c6dfb102ee6
RBC Capital Upgrades Genmab to Outperform MT
GENMAB : RBC raises its recommendation CF
RBC Upgrades Genmab to Outperform From Sector Perform, Keeps Price Target at DKK2,400 MT
BTIG Adjusts Price Target on Genmab to $47 From $46, Maintains Buy Rating MT
Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating MT
GENMAB : A good start to 2024; guidance unchanged Alphavalue
GENMAB : Genmab is available at a bargain price Alphavalue
BMO Capital Upgrades Genmab to Outperform From Market Perform, Adjusts Price Target to $48 From $46 MT
RBC Cuts Price Target on Genmab to DKK2,400 From DKK2,500, Keeps Sector Perform Rating MT
GENMAB : A profitability miss but the market welcomed the better-than-expected sales guidance + share buybacks Alphavalue
HC Wainwright Raises Price Target on Genmab to $50 From $49, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on Genmab to $32 From $33, Maintains Underweight Rating MT
HC Wainwright Adjusts Price Target on Genmab to $49 From $51, Maintains Buy Rating MT
GENMAB : Better-than-expected Q3; lower-end of sales guidance upgraded Alphavalue
GENMAB : Factoring in some caution Alphavalue
BTIG Raises Price Target on Genmab to $46 From $44, Maintains Buy Rating MT
GENMAB : Incorporating R&D priorities; attractiveness remains intact Alphavalue
BTIG Starts Genmab at Buy With $44 Price Target MT
GENMAB : A good Q2 + improved sales guidance Alphavalue
HC Wainwright Adjusts Price Target on Genmab to $51 From $47, Keeps Buy Rating MT
HC Wainwright Adjusts Price Target on Genmab to $47 From $46, Maintains Buy Rating MT
GENMAB : Mixed Q1; attractiveness remains intact, despite profitability miss Alphavalue
GENMAB : Promising 2022; even the softer 2023 guidance isn’t a worry Alphavalue
HC Wainwright Adjusts Price Target on Genmab to $46 From $51, Maintains Buy Rating MT
Morgan Stanley Trims Price Target on Genmab to $33 From $34, Maintains Underweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,828 DKK
Average target price
2,446 DKK
Spread / Average Target
+33.83%
High Price Target
3,000 DKK
Spread / Highest target
+64.11%
Low Price Target
1,600 DKK
Spread / Lowest Target
-12.47%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Genmab A/S

Truist Securities
alphavalue Anas Patel
BMO Capital
RBC Capital Markets
HC Wainwright
Morgan Stanley
BTIG
SVB Securities LLC
William Blair & Co.
DNB Markets
Credit Suisse
Bryan, Garnier & Co.
Cowen
SVB Leerink
Guggenheim
Berenberg Bank
Jefferies & Co.
Deutsche Bank Securities
Danske Bank Group
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings